Biomarkers of Aging with Prognostic and Predictive Value in Non-Oncological Diseases

Author(s): Christian Koppelstaetter, Georg Kern, Gert Mayer

Journal Name: Current Medicinal Chemistry

Volume 16 , Issue 27 , 2009

Become EABM
Become Reviewer
Call for Editor


In this review we discuss the current knowledge on Biomarkers of Aging (BoAs) in the context of human diseases and their value as predictive or prognostic markers. The vast majority of studies using BoAs in a clinical context have been undertaken by determining telomere length in peripheral blood mononuclear cells (PBMCs), whereas the expression of cell cycle inhibitors and an increase in advanced glycation end products (AGEs) have rarely been used. Here we summarize the impact of BoAs on non-oncological, hematological, cardiovascular, metabolic, renal and neurological diseases, as well as on overall survival. The specific methodologies utilized are described and evaluated for their high-throughput potential.

Keywords: Biomarkers, BoAs, Predictive, Prognostic, Telomere, Aging, Outcome

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Page: [3469 - 3475]
Pages: 7
DOI: 10.2174/092986709789057644
Price: $65

Article Metrics

PDF: 8